| Literature DB >> 35742116 |
Fabiana Ruggiero1, Linda Lombi2, Maria Takeko Molisso1, Giorgio Fiore1, Eleonora Zirone1, Roberta Ferrucci3, Elena Pirola1, Marco Locatelli1, Sergio Barbieri1, Francesca Mameli1.
Abstract
Traditionally, medical care and research in Parkinson's disease (PD) have been conducted through in-person visit. The recent Coronavirus Disease 2019 (COVID-19) pandemic has profoundly impacted the delivery of in-person clinical care. We conducted an online survey to investigate the impact of COVID-19 on access to telehealth care, interviewing both PD patients and neurologists. Survey responses were collected from 1 March to 31 May 2021 through an anonymous, self-reported questionnaire, on the 'Qualtrics' platform. In total, 197 patients and 42 neurologists completed the survey. In our sample, 37.56% of PD patients and 88.10% of neurologists reported having used alternatives to in-person visits, while 13.70% of PD patients and 40.48% of neurologists used telemedicine. Data showed that respondents were generally satisfied with the use of telemedicine during the COVID-19 pandemic. The relational dimension between patient and neurologist seems to be the factor that most positively affected the telemedicine experience, contributing greatly to a more patient-centred care. Current findings suggest the need to improve the access to telehealth services for patients with PD. The technology has the potential to improve the care of frail patients, especially when availability of face-to-face visits is limited.Entities:
Keywords: COVID-19; E-health; Parkinson’s disease; survey; telehealth; telemedicine; telerehabilitation
Year: 2022 PMID: 35742116 PMCID: PMC9222237 DOI: 10.3390/healthcare10061065
Source DB: PubMed Journal: Healthcare (Basel) ISSN: 2227-9032
List of indicators, definitions, and variables.
| Indicators | Definition | Variables |
|---|---|---|
| satisfaction | subjective evaluation of whether the user’s expectations were met | -overall satisfaction |
| experience | evaluation of the user’s experience of a healthcare service: the experience can be objective (e.g., waiting time) or subjective (e.g., level of patient-centredness) | -patient-reported experience measures |
| technical quality | subjective evaluation of the quality of the technology used | -audio and picture (video) |
| effectiveness | objective/subjective assessment that a telehealth interaction helped improve the health status or well-being of a patient | -quality of life |
| usefulness/perceived usefulness | objective or subjective assessment that a telehealth interaction produced some benefit or met the purpose of the interaction | -convenience |
| effect on interaction | subjective assessment that the modality of communication affected clinician–patient or clinician–clinician interaction | -communication style |
Demographic data of PD patients and telehealth groups.
| Demographic Data | 197 | 74 | 27 | 20 | |
|---|---|---|---|---|---|
| Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | ||
| age (years) | 65.65 ± 10.26 | 63.11 ± 10.15 | 60.63 ± 10.78 | 60.75 ± 11.12 | |
| education (years) | 13.49 ± 3.93 | 13.72 ± 3.96 | 14.11 ± 3.75 | 14.5 ± 3.28 | |
| disease duration (years) | 9.67 ± 6.66 | 9.65 ± 6.24 | 9.96 ± 7.36 | 9.05 ± 5.58 | |
| gender | male | 97 (49.24) | 33 (44.60) | 12 (44.44) | 10 (50) |
| female | 100 (50.76) | 41 (55.40) | 15 (55.56) | 10 (50) | |
| occupation | unemployed | 12 (6.09) | 10 (13.52) | 5 (18.52) | 4 (20) |
| working | 46 (23.35) | 17 (22.97) | 7 (25.93) | 6 (30) | |
| retired | 134 (68.02) | 45 (60.81) | 14 (51.85) | 10 (50) | |
| other | 5 (2.54) | 2 (2.70) | 1 (3.70) | 0 (0) | |
| area of residence | northern Italy | 120 (60.91) | 44 (59.46) | 16 (59.26) | 11 (55) |
| central-southern Italy | 77 (39.09) | 30 (40.54) | 11 (40.74) | 9 (45) | |
| home assistance | no | 21 (10.66) | 11 (14.86) | 5 (18.52) | 5 (25) |
| yes | 176 (89.34) | 63 (85.14) | 22 (81.48) | 15 (75) | |
| disease diagnosis | Parkinson’s disease | 168 (85.28) | 67 (90.54) | 27 (96.30) | 19 (95) |
| atypical parkinsonisms | 29 (14.72) | 7 (9.46) | 0 (0) | 1 (5) | |
| disease grade | slight | 48 (24.36) | 22 (29.73) | 11 (40.74) | 9 (45) |
| mild | 27 (13.71) | 14 (18.92) | 6 (22.22) | 4 (20) | |
| moderate | 60 (30.46) | 18 (24.32) | 6 (22.22) | 4 (20) | |
| moderate-severe | 44 (22.33) | 15 (20.27) | 2 (7.41) | 1 (5) | |
| severe | 18 (9.14) | 5 (6.76) | 2 (7.41) | 2 (10) | |
| comorbidity | psychiatric symptoms | 13 (6.60) | 3 (4.05) | 0 (0) | 0 (0) |
| cognitive impairment | 14 (7.11) | 5 (6.76) | 2 (7.41) | 1 (5) | |
| none | 162 (82.23) | 64 (86.49) | 23 (85.19) | 18 (90) | |
| psychiatric symptoms and cognitive impairment | 2 (1.02) | 1 (1.35) | 1 (3.70) | 1 (5) | |
| na | 6 (3.04) | 1 (1.35) | 1 (3.70) | 0 (0) | |
| previous use of telehealth | no | 170 (86.29) | 51 (68.92) | 19 (70.37) | 15 (75) |
| yes | 27 (13.71) | 23 (31.08) | 8 (29.63) | 5 (25) | |
| use of telehealth during COVID-19 | no | 123 (62.44) | 0 (0) | 0 (0) | 0 (0) |
| yes | 74 (37.56) | 74 (100) | 27 (100) | 20 (100) | |
| telehealth technical support | no | 47 (23.86) | 47 (63.51) | 14 (51.85) | 13 (65) |
| yes | 26 (13.20) | 26 (35.14) | 13 (48.15) | 7 (35) | |
| na | 124 (62.94) | 1 (1.35) | 0 (0) | 0 (0) | |
| main reason(s) for consultation | follow up | 23 (11.68) | 23 (31.08) | 11 (40.74) | 7 (35) |
| drug prescriptions | 11 (5.58) | 11 (14.86) | 5 (18.52) | 4 (20) | |
| DBS parameters regulation | 2 (1.02) | 2 (2.70) | 0 (0) | 0 (0) | |
| side-effect to drugs | 6 (3.04) | 6 (8.12) | 4 (14.81) | 3 (15) | |
| other | 8 (4.06) | 8 (10.81) | 3 (11.12) | 3 (15) | |
| mixed condition | 22 (11.17) | 22 (29.73) | 4 (14.81) | 3 (15) | |
| na | 125 (63.45) | 2 (2.70) | 0 (0) | 0 (0) | |
| telehealth suggested by | doctor | 46 (23.35) | 46 (62.16) | 20 (74.07) | 15 (75) |
| patient’s associations | 9 (4.57) | 9 (12.16) | 5 (18.52) | 3 (15) | |
| patients | 1 (0.51) | 1 (1.35) | 0 (0) | 0 (0) | |
| internet | 5 (2.54) | 5 (6.76) | 0 (0) | 0 (0) | |
| other | 12 (6.09) | 12 (16.22) | 2 (7.41) | 2 (10) | |
| na | 124 (62.94) | 1 (1.35) | 0 (0) | 0 (0) | |
| telehealth modality | none | 123 (62.44) | 0 (0) | 0 (0) | 0 (0) |
| telephone | 10 (5.07) | 10 (13.52) | 0 (0) | 0 (0) | |
| sms | 2 (1.02) | 2 (2.70) | 0 (0) | 0 (0) | |
| chat | 1 (0.51) | 1 (1.35) | 0 (0) | 0 (0) | |
| 34 (17.25) | 34 (45.94) | 0 (0) | 0 (0) | ||
| video consultation | 27 (13.71) | 27 (36.49) | 27 (100) | 20 (100) | |
Legend. na: data not available.
Construct response data of PD patients and neurologists.
| 20 Patients | 17 Neurologists | ||
|---|---|---|---|
| perceived usefulness | strongly disagree | 0 (0) | 0 (0) |
| quite in disagreement | 1 (5) | 1 (5.88) | |
| neither in agreement nor disagreement | 1 (5) | 3 (17.65) | |
| quite in agreement | 5 (25) | 9 (52.94) | |
| strongly agree | 13 (65) | 4 (23.53) | |
| technical quality | strongly disagree | 0 (0) | 1 (5.88) |
| quite in disagreement | 0 (0) | 1 (5.88) | |
| neither in agreement nor disagreement | 2 (10) | 4 (23.53) | |
| quite in agreement | 7 (35) | 7 (41.18) | |
| strongly agree | 11 (55) | 4 (23.53) | |
| effectiveness | strongly disagree | 0 (0) | 0 (0) |
| quite in disagreement | 0 (0) | 1 (5.88) | |
| neither in agreement nor disagreement | 3 (15) | 1 (5.88) | |
| quite in agreement | 8 (40) | 11 (64.71) | |
| strongly agree | 9 (45) | 4 (23.53) | |
| effect on interaction | strongly disagree | 0 (0) | 0 (0) |
| quite in disagreement | 1 (5) | 1 (5.88) | |
| neither in agreement nor disagreement | 1 (5) | 1 (5.88) | |
| quite in agreement | 7 (35) | 13 (76.47) | |
| strongly agree | 11 (55) | 2 (11.76) | |
| experience | strongly disagree | 0 (0) | 0 (0) |
| quite in disagreement | 0 (0) | 0 (0) | |
| neither in agreement nor disagreement | 2 (10) | 4 (23.53) | |
| quite in agreement | 7 (35) | 9 (52.94) | |
| strongly agree | 11 (55) | 4 (23.53) | |
| satisfaction | strongly disagree | 0 (0) | 0 (0) |
| quite in disagreement | 0 (0) | 0 (0) | |
| neither in agreement nor disagreement | 2 (10) | 2 (11.76) | |
| quite in agreement | 8 (40) | 12 (70.59) | |
| strongly agree | 10 (50) | 3 (17.65) |
Correlations between constructs for PD patients and neurologists.
| Usefulness/ | Technical Quality | Effectiveness | Effect on Interaction | Experience | Satisfaction | |
|---|---|---|---|---|---|---|
| 20 patients | ||||||
| usefulness/perceived usefulness | - | ρ = 0.67 | ρ = 0.67 | ρ = 0.67 | ρ = 0.67 | ρ = 0.61 |
| technical quality | ρ = 0.67 | - | ρ = 0.49 | ρ = 0.54 | ρ = 0.54 | ρ = 0.58 |
| effectiveness | ρ = 0.67 | ρ = 0.49 | - | ρ = 0.84 * | ρ = 0.84 * | ρ = 0.74 * |
| effect on interaction | ρ = 0.67 | ρ = 0.54 | ρ = 0.84 * | - | ρ = 0.99 * | ρ = 0.89 * |
| experience | ρ = 0.67 | ρ = 0.54 | ρ = 0.84 * | ρ = 0.99 * | - | ρ = 0.89 * |
| satisfaction | ρ = 0.61 | ρ = 0.58 | ρ = 0.74 * | ρ = 0.89 * | ρ = 0.89 * | - |
| 17 neurologists | ||||||
| usefulness/perceived usefulness | - | ρ = 0.76 * | ρ = 0.75 * | ρ = 0.50 | ρ = 0.76 * | ρ = 0.65 |
| technical quality | ρ = 0.76 * | - | ρ = 0.62 | ρ = 0.37 | ρ = 0.57 | ρ = 0.41 |
| effectiveness | ρ = 0.75 * | ρ = 0.62 | - | ρ = 0.41 | ρ = 0.73 * | ρ = 0.37 |
| effect on interaction | ρ = 0.50 | ρ = 0.37 | ρ = 0.41 | - | ρ = 0.71 * | ρ = 0.69 * |
| experience | ρ = 0.76 * | ρ = 0.57 | ρ = 0.73 * | ρ = 0.71 * | - | ρ = 0.80 * |
| satisfaction | ρ = 0.65 | ρ = 0.41 | ρ = 0.37 | ρ = 0.69 * | ρ = 0.80 * | - |
Legend. Spearman’s rank coefficient ρ ≥ 0.7 and p < 0.05. *: indicate statistical significance.
Demographic data of neurologist and telehealth groups.
| Demographic Data | 42 | 37 | 17 | |
|---|---|---|---|---|
| Mean ± SD | Mean ± SD | Mean ± SD | ||
| age (years) | 50.55 (12.52) | 51.08 (11.15) | 52.47 (10.47) | |
| gender | male | 19 (45.24) | 16 (43.24) | 8 (47.06) |
| female | 23 (54.76) | 21 (56.76) | 9 (52.94) | |
| working region | northern Italy | 31 (73.81) | 28 (75.68) | 14 (82.35) |
| central-southern Italy | 11 (26.19) | 9 (24.32) | 3 (17.65) | |
| working place | public hospital | 22 (52.38) | 21 (56.76) | 10 (58.82) |
| private hospital | 4 (9.52) | 4 (10.81) | 2 (11.76) | |
| private practice | 3 (7.14) | 3 (8.11) | 0 (0) | |
| university | 5 (11.91) | 3 (8.11) | 1 (5.88) | |
| other | 8 (19.05) | 6 (16.22) | 4 (23.53) | |
| working experience (years) | 0–5 | 6 (14.28) | 4 (10.81) | 1 (5.88) |
| 6–15 | 11 (26.19) | 11 (29.73) | 5 (29.41) | |
| 16–25 | 10 (23.81) | 9 (24.32) | 4 (23.53) | |
| 26–35 | 8 (19.05) | 7 (18.92) | 5 (29.41) | |
| >35 | 7 (16.67) | 6 (16.22) | 2 (11.76) | |
| previous use of telehealth | no | 12 (28.57) | 7 (18.92) | 2 (11.76) |
| yes | 30 (71.43) | 30 (81.08) | 15 (88.24) | |
| use of telehealth during COVID-19 | no | 5 (11.90) | 0 (0) | 0 (0) |
| yes | 37 (88.10) | 37 (100) | 17 (100) | |
| telehealth suggested by | hospital | 14 (33.34) | 14 (37.84) | 7 (41.18) |
| themselves | 16 (38.09) | 16 (43.24) | 7 (41.18) | |
| patient | 5 (11.90) | 5 (13.51) | 3 (17.65) | |
| na | 7 (16.67) | 2 (5.41) | 0 (0) | |
| institutional platform | no | 23 (54.76) | 23 (62.16) | 9 (52.94) |
| yes | 12 (28.57) | 12 (32.43) | 8 (47.06) | |
| na | 7 (16.67) | 2 (5.41) | 0 (0) | |
| telehealth technical support | no | 4 (9.52) | 4 (10.81) | 3 (17.65) |
| yes | 7 (16.67) | 7 (18.92) | 5 (29.41) | |
| na | 31 (73.81) | 26 (70.27) | 9 (52.94) | |
| institutional guidelines | no | 6 (14.28) | 6 (16.22) | 5 (29.41) |
| yes | 5 (11.90) | 5 (13.51) | 3 (17.65) | |
| na | 31 (73.81) | 26 (70.27) | 9 (52.94) | |
| main reason(s) for consultation | follow up | 4 (9.52) | 4 (10.81) | 3 (17.65) |
| drug prescriptions | 2 (4.76) | 2 (5.41) | 1 (5.88) | |
| DBS parameters regulation | 0 (0) | 0 (0) | 0 (0) | |
| side-effect to drugs | 2 (4.76) | 2 (5.41) | 0 (0) | |
| other | 0 (0) | 0 (0) | 0 (0) | |
| mixed condition | 24 (57.14) | 24 (64.86) | 13 (76.47) | |
| na | 10 (23.82) | 5 (13.51) | 0 (0) | |
| telehealth modality | none | 0 (0) | 0 (0) | 0 (0) |
| telephone | 2 (4.76) | 2 (5.41) | 0 (0) | |
| sms | 0 (0) | 0 (0) | 0 (0) | |
| chat | 1 (2.38) | 1 (2.70) | 0 (0) | |
| 12 (28.57) | 12 (32.43) | 0 (0) | ||
| video consultation | 17 (40.48) | 17 (45.94) | 17 (100) | |
| na | 10 (23.81) | 5 (13.51) | 0 (0) | |
Legend. na: data not available.